High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance)
      QxMD      Google Scholar   
Citation:
Clin Cancer Res vol 24 (13) 3053-58
Year:
2018
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
Yes
SDC:
No
Book Volume:
7
Parents:
2745  
Children:
None
Program:
TRP
Primary Committee:
Correl Sci NOS
Sec. Committees:
   
Pharmas:
 
Grants:
U10CA180821, U10CA180882, U24CA196171, U10CA025224 U10CA180790  
Corr. Author:
 
Authors:
                                 
Networks:
LAPS-IL057, LAPS-MN026, PR028   
Study
Multiple Studies, or Legacy Studies in Alliance Study:
NCCTG-N0337, NCCTG-N98-32-52
Phases:
2
Keywords: